The Experts below are selected from a list of 9888 Experts worldwide ranked by ideXlab platform
Michael W Beaty - One of the best experts on this subject based on the ideXlab platform.
-
concomitant occurrence of sinus histiocytosis with massive lymphadenopathy and nodal Marginal Zone Lymphoma
Archives of Pathology & Laboratory Medicine, 2011Co-Authors: Changlee S Pang, David D. Grier, Michael W BeatyAbstract:Abstract Sinus histiocytosis with massive lymphadenopathy (SHML), also known as Rosai-Dorfman disease, is a rare self-limiting disorder of histiocytes with unknown etiology. Sinus histiocytosis with massive lymphadenopathy is most common in children and young adults and is characterized by painless lymphadenopathy. Histologically there is a proliferation of sinus histiocytes with lymphophagocytosis or emperipolesis. On rare occasions, SHML has been associated with Lymphoma, usually involving different anatomic sites and developing at different times. We report a case of concomitant SHML and nodal Marginal Zone Lymphoma involving the same lymph node without involvement of other nodal or extranodal sites. The presence of concomitant SHML within the lymph node involved by nodal Marginal Zone Lymphoma may represent the responsiveness of SHML histiocytes to B-cell–derived cytokines in lymphoproliferative disorders. To our knowledge, this is the first description of concomitant occurrence of SHML and nodal marg...
-
Concomitant occurrence of sinus histiocytosis with massive lymphadenopathy and nodal Marginal Zone Lymphoma.
Archives of pathology & laboratory medicine, 2011Co-Authors: Changlee S Pang, David D. Grier, Michael W BeatyAbstract:Sinus histiocytosis with massive lymphadenopathy (SHML), also known as Rosai-Dorfman disease, is a rare self-limiting disorder of histiocytes with unknown etiology. Sinus histiocytosis with massive lymphadenopathy is most common in children and young adults and is characterized by painless lymphadenopathy. Histologically there is a proliferation of sinus histiocytes with lymphophagocytosis or emperipolesis. On rare occasions, SHML has been associated with Lymphoma, usually involving different anatomic sites and developing at different times. We report a case of concomitant SHML and nodal Marginal Zone Lymphoma involving the same lymph node without involvement of other nodal or extranodal sites. The presence of concomitant SHML within the lymph node involved by nodal Marginal Zone Lymphoma may represent the responsiveness of SHML histiocytes to B-cell-derived cytokines in lymphoproliferative disorders. To our knowledge, this is the first description of concomitant occurrence of SHML and nodal Marginal Zone Lymphoma.
Marco Paulli - One of the best experts on this subject based on the ideXlab platform.
-
Splenic Marginal Zone Lymphoma: hydra with many heads?
Haematologica, 2010Co-Authors: Luca Arcaini, Marco PaulliAbstract:In this issue of the Journal, Baseggio et al. [1][1] report on a series of 24 patients with CD5-positive, t(11;14)-negative splenic Marginal Zone Lymphoma (SMZL) diagnosed by means of cytology and flow cytometry of peripheral blood. All the patients were splenectomized at diagnosis or during follow-
-
Nodal Marginal Zone Lymphoma: current knowledge and future directions of an heterogeneous disease
European Journal of Haematology, 2009Co-Authors: Luca Arcaini, Marco Lucioni, Emanuela Boveri, Marco PaulliAbstract:Nodal Marginal Zone Lymphoma (NMZL) is a defined, separate clinicopathological entity. NMZL is a B-cell neoplasm originated in the lymph node, whose histology resembles the nodal infiltration by mucosa-associated lymphoid tissue- or splenic-type Marginal Zone Lymphoma, in the absence of clinical evidence of extranodal or spleen disease. The lack of characteristic phenotypic or molecular diagnostic findings is still hampering the reproducibility of this diagnosis. Herein, we review the main morphological and immunophenotypical markers, discussing the differential with other overlapping entities. We also summarize the clinical features and outcome of this rare Lymphoma and we discuss the possible association with hepatitis C virus infection.
Changlee S Pang - One of the best experts on this subject based on the ideXlab platform.
-
concomitant occurrence of sinus histiocytosis with massive lymphadenopathy and nodal Marginal Zone Lymphoma
Archives of Pathology & Laboratory Medicine, 2011Co-Authors: Changlee S Pang, David D. Grier, Michael W BeatyAbstract:Abstract Sinus histiocytosis with massive lymphadenopathy (SHML), also known as Rosai-Dorfman disease, is a rare self-limiting disorder of histiocytes with unknown etiology. Sinus histiocytosis with massive lymphadenopathy is most common in children and young adults and is characterized by painless lymphadenopathy. Histologically there is a proliferation of sinus histiocytes with lymphophagocytosis or emperipolesis. On rare occasions, SHML has been associated with Lymphoma, usually involving different anatomic sites and developing at different times. We report a case of concomitant SHML and nodal Marginal Zone Lymphoma involving the same lymph node without involvement of other nodal or extranodal sites. The presence of concomitant SHML within the lymph node involved by nodal Marginal Zone Lymphoma may represent the responsiveness of SHML histiocytes to B-cell–derived cytokines in lymphoproliferative disorders. To our knowledge, this is the first description of concomitant occurrence of SHML and nodal marg...
-
Concomitant occurrence of sinus histiocytosis with massive lymphadenopathy and nodal Marginal Zone Lymphoma.
Archives of pathology & laboratory medicine, 2011Co-Authors: Changlee S Pang, David D. Grier, Michael W BeatyAbstract:Sinus histiocytosis with massive lymphadenopathy (SHML), also known as Rosai-Dorfman disease, is a rare self-limiting disorder of histiocytes with unknown etiology. Sinus histiocytosis with massive lymphadenopathy is most common in children and young adults and is characterized by painless lymphadenopathy. Histologically there is a proliferation of sinus histiocytes with lymphophagocytosis or emperipolesis. On rare occasions, SHML has been associated with Lymphoma, usually involving different anatomic sites and developing at different times. We report a case of concomitant SHML and nodal Marginal Zone Lymphoma involving the same lymph node without involvement of other nodal or extranodal sites. The presence of concomitant SHML within the lymph node involved by nodal Marginal Zone Lymphoma may represent the responsiveness of SHML histiocytes to B-cell-derived cytokines in lymphoproliferative disorders. To our knowledge, this is the first description of concomitant occurrence of SHML and nodal Marginal Zone Lymphoma.
Werner Kempf - One of the best experts on this subject based on the ideXlab platform.
-
igg4 expression in primary cutaneous Marginal Zone Lymphoma a multicenter study
Applied Immunohistochemistry & Molecular Morphology, 2017Co-Authors: Aieska De Souza, Marianne Tinguely, Amrita Goyal, Lyn M. Duncan, Judith A Ferry, Daniel R Burghart, Heinz Kutzner, Werner KempfAbstract:Background:Primary cutaneous Marginal Zone Lymphoma (PCMZL) is the second most common B-cell Lymphoma of the skin. A recent study has demonstrated a strikingly high prevalence of immunoglobulin (Ig)G4 expression in PCMZL with plasmacytic differentiation.Objective:The objective was to investigate the
-
Disseminated anetoderma in a patient with nodal Epstein-Barr virus-associated classical Hodgkin Lymphoma: Anetodermic form of a concurrent discordant cutaneous Marginal Zone Lymphoma.
International journal of dermatology, 2016Co-Authors: Anupam Varshney, Tarang Goyal, Vijay Zawar, Marianne Tinguely, Werner KempfAbstract:Patients with a Lymphoma have an increased risk of developing a second lymphoproliferative disorder. The association of nodal Hodgkin Lymphoma and primary cutaneous Marginal Zone Lymphoma (MALT type) is exceptional, and only very few cases have been documented. Anetoderma represents a circumscribed loss or rarefication of elastic fibers. Different underlying processes may result in anetoderma, including cutaneous Marginal Zone Lymphoma. We report a 50-year-old male patient with Epstein-Barr virus (EBV)-associated nodal Hodgkin Lymphoma who presented with disseminated anetodermic skin lesions. Biopsies of the skin lesions revealed a B-cell infiltrate containing monoclonal plasma cells but without detection of EBV. The skin lesions represent an anetodermic form of primary cutaneous Marginal Zone Lymphoma. It is the first case report of an association of anetodermic cutaneous Marginal Zone Lymphoma and a synchronous EBV-associated nodal Hodgkin Lymphoma.
Catherine Thieblemont - One of the best experts on this subject based on the ideXlab platform.
-
Updates in Splenic and Nodal Marginal Zone Lymphoma
2017Co-Authors: Catherine ThieblemontAbstract:This video reviews updates on the treatment and biology of splenic and nodal Marginal Zone Lymphoma.
-
optimizing therapy for nodal Marginal Zone Lymphoma
Blood, 2016Co-Authors: Catherine Thieblemont, T Molina, Frederic DaviAbstract:Nodal Marginal Zone Lymphoma (NMZL) is a rare form of indolent small B-cell Lymphoma which has only been clearly identified in the last 2 decades and which to date remains incurable. Progress in therapeutic management has been slow, largely due to the very small number of patients treated and the heterogeneity of treatments administered; thus, standard-of-care treatment is currently nonspecific for this Lymphoma entity. In this review, treatments routinely used to manage adult NMZL patients are presented, principally based on immunochemotherapy (when treatment is needed). Biological research behind the key axes of agents currently under development is described; development of novel agents is heavily based on data from gene profiling and genome-wide sequencing research, uncovering a number of critical deregulated pathways specific to NMZL tumors. These include B-cell receptor, JAK/STAT, NF-κB, NOTCH, and Toll-like receptor signaling pathways, as well as intracellular processes such as the cell cycle, chromatin remodeling, and transcriptional regulation in terms of epigenetic modifiers, histones, or transcriptional co-repressors, along with immune escape via T-cell-mediated tumor surveillance. These pathways are examined in detail and a projection of how the field may evolve in the near future for an efficient personalized treatment approach for NMZL patients is presented.
-
Splenic Marginal Zone Lymphoma: Current Knowledge and Future Directions
Oncology (Williston Park N.Y.), 2012Co-Authors: Catherine Thieblemont, Frederic Davi, Maria-elena Noguera, Josette Brière, Francesco Bertoni, Emanuele Zucca, Alexandra Traverse-glehen, Pascale Felman, Françoise Berger, Gilles SallesAbstract:In this article, we review the current knowledge on the biological findings, clinical features, and therapeutic approaches for splenic Marginal Zone Lymphoma.
-
Non-MALT Marginal Zone Lymphoma.
Current opinion in hematology, 2011Co-Authors: Catherine Thieblemont, Frederic Davi, Maria-elena Noguera, Josette BrièreAbstract:Purpose of review Non-MALT Marginal Zone Lymphoma regroups two subtypes of Lymphoma, the splenic Marginal Zone Lymphoma (SMZL) and the nodal Marginal Zone Lymphoma (NMZL). Although they share a common cell of origin from the ‘Marginal Zone’, they display different clinical characteristics, reflecting probable biological variations according to the organ. Recent findings Within the past decade, new data regarding pathogenic mechanisms as well as therapeutic advances have been reported. Summary SMZL and NMZL often present with disseminated disease at diagnosis, with specific clinical presentation, SMZL with predominant enlarged splenomegaly and NMZL with disseminated nodal involvement. Diagnosis may be difficult among the small B-cell Lymphomas and criteria for diagnosis have been recently improved. The therapeutic approaches comprise splenectomy for SMZL, and immunochemotherapy for both of SMZL and NMZL, but with no consensus about the best treatment, except when associated with hepatitis C virus. This review addresses the current knowledge on the biological findings, clinical features and therapeutic approaches for the individual SMZLs and NMZLs.